June 2022

Descriptive Analysis of Acute Ischemic Stroke in COVID-19 Patients Through The Course Of The COVID-19 Pandemic

Amman Bhasin  
Wayne State University, amman.bhasin@med.wayne.edu

Jay Liuhong Liu  
Wayne State University

Keval Shah  
Wayne State University

Amin Marji  
Wayne State University

Ricky Sareini  
Wayne State University

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wayne.edu/som_srs

Part of the Neurology Commons, and the Other Medical Sciences Commons

Recommended Citation  
Bhasin, Amman; Liu, Jay Liuhong; Shah, Keval; Marji, Amin; Sareini, Ricky; Rao, Shishir; Mohamed, Wazim; Rajamani, Kumar; Chamiraju, Parthasarathi; and Khawaja, Ayaz, "Descriptive Analysis of Acute Ischemic Stroke in COVID-19 Patients Through The Course Of The COVID-19 Pandemic" (2022). Medical Student Research Symposium. 187.  
https://digitalcommons.wayne.edu/som_srs/187

This Research Abstract is brought to you for free and open access by the School of Medicine at DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an authorized administrator of DigitalCommons@WayneState.
Authors
Amman Bhasin, Jay Liuhong Liu, Keval Shah, Amin Marji, Ricky Sareini, Shishir Rao, Wazim Mohamed, Kumar Rajamani, Parthasarathi Chamiraju, and Ayaz Khawaja
Title:
Descriptive Analysis of Acute Ischemic Stroke in COVID-19 Patients Through The Course Of The COVID-19 Pandemic

Abstract:
Coronavirus disease 2019 (COVID-19) has been associated with Acute Ischemic Stroke (AIS). Here, we characterize our institutional experience with management of COVID-19 and AIS. Baseline demographics, clinical, imaging, and outcomes data were determined in patients with COVID-19 and AIS presenting within March 2020 thru October 2020, and November 2020 thru August 2021, based on institutional COVID-19 hospitalization volume. Of 2512 COVID-19 patients, 35 (1.39%, mean age 63.3 years, 54% women) had AIS. AIS recognition was frequently delayed after COVID-19 symptoms (median 19.5 days). Four patients (31%) were on therapeutic anticoagulation at AIS recognition. AIS mechanism was undetermined or due to multiple etiologies in most cases (n=20, 57%). Three patients underwent IV TPA, and three underwent mechanical thrombectomy, of which two suffered re-occlusion. Three patients had incomplete mRNA vaccination course. Fourteen (40%) died with 26 (74%) having poor outcomes. Critical COVID-19 severity was associated with worsened mortality (p=0.02). More patients (12/16; 75%) had either worsening or similar 3-month functional outcomes, than those with improvement, indicating the devastating impact of co-existing AIS and COVID-19. Comparative analysis showed that patients in the later cohort had earlier AIS presentation, less stroke risk factors, more comprehensive workup, more defined stroke mechanisms, less instance of critical COVID-19 severity, more utilization of IV TPA, and a trend towards worse outcomes for the sub-group of mild-to-moderate COVID-19 severity. AIS incidence, NIHSS, and overall outcomes were similar. Further studies should investigate outcomes beyond 3 months and their predictive factors, impact of completed vaccination course, and access to neurologic care.

Keywords:
COVID-19; SARS-CoV-2; Acute ischemic stroke; Large vessel occlusion; Encephalopathy